Last reviewed · How we verify
NCT05351866
Digital Therapeutic for Adolescent Depressive Symptoms in Hematology, Oncology, and Weight Management
NA trial testing CBT-based mobile intervention for depression in Depression in 7 participants. Terminated before completion.
26 June 2023
Quick facts
| Lead sponsor | Limbix Health, Inc. |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 7 |
| Start date | 26 January 2023 |
| Primary completion | 26 June 2023 |
| Estimated completion | 26 June 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- CBT-based mobile intervention for depression
- Mobile control with education about depression
Conditions studied
- Depression — all drugs for Depression →
- Depressive Disorder — all drugs for Depressive Disorder →
- Depressive Symptoms — all drugs for Depressive Symptoms →
- Depressive Episode — all drugs for Depressive Episode →
Sponsor
Limbix Health, Inc.
Who can join
Adults 13 to 22, any sex, with Depression or Depressive Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary aims of the proposed research are to assess the feasibility, acceptability, and preliminary evidence of efficacy of a self-guided, cognitive behavioral therapy (CBT)-based mobile app intervention (SparkRx) for the treatment of adolescents presenting with symptoms of depression in specialty medical care settings (e.g.Hematology/Oncology, Weight Management, etc.) at Children's Health System of Texas (CHST).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05351866
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Depression
Currently open trials in the same condition.
- NCT07336238 — Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or · Phase 2 · recruiting
- NCT06906939 — A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression · EARLY_PHASE1 · recruiting
- NCT07517549 — Sexual Health Education During Pregnancy · NA · recruiting
- NCT06408246 — ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression · Phase 2 · recruiting
- NCT07449676 — Effects of an Innovative TCM-based Tui Jing Therapy on Psychological and Neurophysiological Functions in Depression · NA · recruiting
Other Limbix Health, Inc. trials
Trials by the same sponsor.
- NCT05461599 — Digital Therapeutic for Adolescent Depressive Symptoms in Cardiology and Gastroenterology · NA · terminated
- NCT05462652 — Self-guided Treatment for Adolescents Navigating Depression · NA · completed
- NCT04524598 — A CBT-based Mobile Intervention as First Line Treatment for Adolescent Depression During COVID-19 · NA · completed
- NCT04165681 — A Mobile and Virtual Reality Intervention for Adolescent Depression · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05351866 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Limbix Health, Inc.
- Last refreshed: 4 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05351866.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing